VEGFA and neoplasm: Accordingly, VEGF receptor (VEGFR) blockage by the administration of Sunitinib (Sutent®) combined with the VEGF inhibitor Bevacizumab (Avastin®) resulted in a reduction of myeloid infiltrates, decreased tumor vascularity, and prolonged survival in a GBM mouse model [116].